Business
PureTech to Present at Two Investor Conferences
PureTech to Present at Two Investor Conferences.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5942U\n PureTech Health PLC\n 07 April 2021\n \n \n \n \n 7 April 2021\n \n \n PureTech Health plc\n \n \n \n \n \n PureTech to Present at Two Upcoming Investor Conferences\n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that members of the management team will present at the following upcoming virtual investor conferences. Webcasts of the presentations will be available at \n \n \n https://investors.puretechhealth.com/events-presentations\n \n \n .\n \n \n \n \n \n The 19th Annual Virtual Needham Healthcare Conference\n \n \n Presenter: George Farmer, Ph.D., Chief Financial Officer\n \n \n Date: Monday, April 12th, 2021\n \n \n Time: 11:45 AM EDT\n \n \n \n \n \n PureTech Fireside Chat with Liberum\n \n \n Presenters: Bharatt Chowrira, Ph.D., J.D., President and Chief of Business and Strategy; George Farmer, Ph.D., Chief Financial Officer\n \n \n Date: Wednesday, April 28th, 2021\n \n \n Time: 11:00 AM EDT\n \n \n \n \n \n About PureTech Health\n \n \n PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, as of the date of PureTech's most recently filed Registration Statement on Form 20-F, was comprised of 24 therapeutics and therapeutic candidates, including two that have received FDA clearance and European marketing authorization. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team...